Citations

Clear

62 citation(s) found for "Kennedy, Richard".

Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus–Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination
Voigt, Emily A. , Haralambieva, Iana H. , Larrabee, Beth L, Kennedy, Richard B. , Ovsyannikova, Inna G. , Schaid, Daniel J. , Larrabee, Beth R. , Kennedy, Richard , Poland, Gregory A.

Mayo Clinic

The Journal of Infectious Diseases | October 3, 2017 | Volume: 217 | Issue: 4 | Pages: 560-566

10.1093/infdis/jix538 | PMID 29253144 Get It

Newborn Screening for X-Linked Adrenoleukodystrophy
Moser, Ann B. , Jones, Richard O., Hubbard, Walter C., Tortorelli, Silvia , Orsini, Joseph J. , Caggana, Michele, Vogel, Beth , Raymond, Gerald V.

Mayo Clinic

International Journal of Neonatal Screening | December 6, 2016 | Volume: 2 | Issue: 4 | Pages: 15

10.3390/ijns2040015 | PMID 31467997 Get It

Early diagnosis of males with X-linked adrenoleukodystrophy (X-ALD) is essential for preventing loss of life due to adrenal insufficiency and for timely therapy of the childhood cerebral form of X-ALD with hematopoietic cell transplantation. This article describes X-ALD, the current therapies, the history of the development of the newborn screening test, the approval by the Secretary of Health and Human Services for the addition of X-ALD newborn screening to the recommended uniform panel of disorders screened as newborns (RUSP) and the successful implementation of X-ALD newborn screening in the state of New York beginning on 30 December 2013. Follow-up guidelines that have been established in New York are outlined. Based on the success of newborn screening in New York, and early results in Connecticut, where X-ALD newborn screening started in December 2015, and in California, where X-ALD newborn screening began in September 2016, we are confident and hopeful that X-ALD newborn screening will expand to include all US states and to countries that have established neonatal screening programs. The Minster of Health in the Netherlands has approved the addition of X-ALD to the newborn screening program with a start date expected in 2017. The states, such as Massachusetts, Illinois, Minnesota, New Jersey, Florida and Washington, that have legislative approval will commence screening as soon as budgetary resources, testing and follow-up procedures are in place.
Statistical Methods for Testing Genetic Pleiotropy
Schaid, Daniel J. , Tong, Xingwei, Larrabee, Beth R. , Kennedy, Richard B. , Sinnwell, Jason P. , Larrabee, Beth, Poland, Gregory A. , Sinnwell, Jason P , Kennedy, Richard

Mayo Clinic

Genetics | August 16, 2016 | Volume: 204 | Issue: 2 | Pages: 483-497

10.1534/genetics.116.189308 | PMID 27527515 Get It

AbstractGenetic pleiotropy is when a single gene influences more than one trait. Detecting pleiotropy and understanding its causes can improve the biological understanding of a gene in multiple ways, yet current multivariate methods to evaluate pleiotropy test the null hypothesis that none of the traits are associated with a variant; departures from the null could be driven by just one associated trait. A formal test of pleiotropy should assume a null hypothesis that one or no traits are associated with a genetic variant. For the special case of two traits, one can construct this null hypothesis based on the intersection-union (IU) test, which rejects the null hypothesis only if the null hypotheses of no association for both traits are rejected. To allow for more than two traits, we developed a new likelihood-ratio test for pleiotropy. We then extended the testing framework to a sequential approach to test the null hypothesis that k+1 traits are associated, given that the null of k traits are associated was rejected. This provides a formal testing framework to determine the number of traits associated with a genetic variant, while accounting for correlations among the traits. By simulations, we illustrate the type I error rate and power of our new methods; describe how they are influenced by sample size, the number of traits, and the trait correlations; and apply the new methods to multivariate immune phenotypes in response to smallpox vaccination. Our new approach provides a quantitative assessment of pleiotropy, enhancing current analytic practice.
The composition of immune cells serves as a predictor of adaptive immunity in a cohort of 50‐ to 74‐year‐old adults
Kennedy, Richard B. , Simon, Whitney L., Gibson, Michael J., Goergen, Krista M., Grill, Diane E. , Oberg, Ann L. , Gibson, Michael J., Poland, Gregory A. , Kennedy, Richard

Mayo Clinic

Immunology | May 18, 2016 | Volume: 148 | Issue: 3 | Pages: 266-275

10.1111/imm.12599 | PMID 27188667 Get It

SummaryInfluenza causes significant morbidity and mortality annually. Although vaccination offers a considerable amount of protection, it is far from perfect, especially in aging populations. This is due to age‐related defects in immune function, a process called immunosenescence. To date, there are no assays or methods to predict or explain variations in an individual's level of response to influenza vaccination. In this study, we measured levels of several immune cell subsets at baseline (Day 0) and at Days 3 and 28 post‐vaccination using flow cytometry. Statistical modelling was performed to assess correlations between levels of cell subsets and Day 28 immune responses – haemagglutination inhibition (HAI) assay, virus neutralizing antibody (VNA) assay, and memory B cell ELISPOT. Changes in several groups of cell types from Day 0 to Day 28 and Day 3 to Day 28 were found to be significantly associated with immune response. Baseline levels of several immune cell subsets, including B cells and regulatory T cells, were able to partially explain variation in memory B‐cell ELISPOT results. Increased expression of HLA‐DR on plasmacytoid dendritic cells after vaccination was correlated with increased HAI and VNA responses. Our data suggest that the expression of activation markers (HLA‐DR and CD86) on various immune cell subsets, as well as the relative distribution of cell subsets, both have value in predicting immune responses to influenza vaccination in older individuals.
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
Shen, Ying , Nitta, Masayuki, Futalan, Diahnn, Treiber, Jeffrey M. , Taich, Zack, Stevens, Deanna M., Wykosky, Jill, Chen, Hong-Zhuan, Becher, Oren J. , Kennedy, Richard D. , Cavenee, Webster K. , Desai, Arshad , Chen, Clark C. , Li, Jie , Steed, Tyler , Taich, Zack, Carter, Bob S. , Esashi, Fumiko , Sarkaria, Jann N. , Furnari, Frank B.

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 14 | Pages: 11751-11767

10.18632/oncotarget.3996 | PMID 26059434 Get It

Fine Mapping Causal Variants with an Approximate Bayesian Method Using Marginal Test Statistics
Chen, Wenan , Larrabee, Beth R. , Ovsyannikova, Inna G. , Kennedy, Richard B. , Haralambieva, Iana H. , Schaid, Daniel J. , Poland, Gregory A. , Kennedy, Richard

Mayo Clinic

Genetics | May 7, 2015 | Volume: 200 | Issue: 3 | Pages: 719-736

10.1534/genetics.115.176107 | PMID 25948564 Get It

AbstractTwo recently developed fine-mapping methods, CAVIAR and PAINTOR, demonstrate better performance over other fine-mapping methods. They also have the advantage of using only the marginal test statistics and the correlation among SNPs. Both methods leverage the fact that the marginal test statistics asymptotically follow a multivariate normal distribution and are likelihood based. However, their relationship with Bayesian fine mapping, such as BIMBAM, is not clear. In this study, we first show that CAVIAR and BIMBAM are actually approximately equivalent to each other. This leads to a fine-mapping method using marginal test statistics in the Bayesian framework, which we call CAVIAR Bayes factor (CAVIARBF). Another advantage of the Bayesian framework is that it can answer both association and fine-mapping questions. We also used simulations to compare CAVIARBF with other methods under different numbers of causal variants. The results showed that both CAVIARBF and BIMBAM have better performance than PAINTOR and other methods. Compared to BIMBAM, CAVIARBF has the advantage of using only marginal test statistics and takes about one-quarter to one-fifth of the running time. We applied different methods on two independent cohorts of the same phenotype. Results showed that CAVIARBF, BIMBAM, and PAINTOR selected the same top 3 SNPs; however, CAVIARBF and BIMBAM had better consistency in selecting the top 10 ranked SNPs between the two cohorts. Software is available at https://bitbucket.org/Wenan/caviarbf.
Profiling of Measles-Specific Humoral Immunity in Individuals Following Two Doses of MMR Vaccine Using Proteome Microarrays
Haralambieva, Iana H. , Simon, Whitney L., Kennedy, Richard B. , Ovsyannikova, Inna G. , Warner, Nathaniel D. , Grill, Diane E. , Poland, Gregory A. , Kennedy, Richard

Mayo Clinic

Viruses | March 10, 2015 | Volume: 7 | Issue: 3 | Pages: 1113-1133

10.3390/v7031113 | PMID 25763865 Get It

Introduction: Comprehensive evaluation of measles-specific humoral immunity after vaccination is important for determining new and/or additional correlates of vaccine immunogenicity and efficacy. Methods: We used a novel proteome microarray technology and statistical modeling to identify factors and models associated with measles-specific functional protective immunity in 150 measles vaccine recipients representing the extremes of neutralizing antibody response after two vaccine doses. Results: Our findings demonstrate a high seroprevalence of antibodies directed to the measles virus (MV) phosphoprotein (P), nucleoprotein (N), as well as antibodies to the large polymerase (L) protein (fragment 1234 to 1900 AA). Antibodies to these proteins, in addition to anti-F antibodies (and, to a lesser extent, anti-H antibodies), were correlated with neutralizing antibody titer and/or were associated with and predictive of neutralizing antibody response. Conclusion: Our results identify antibodies to specific measles virus proteins and statistical models for monitoring and assessment of measles-specific functional protective immunity in vaccinated individuals.
Cytokine Production Associated with Smallpox Vaccine Responses
Simon, Whitney L., Salk, Hannah M., Ovsyannikova, Inna G. , Kennedy, Richard B. , Poland, Gregory A. , Kennedy, Richard

Mayo Clinic

Immunotherapy | November 27, 2014 | Volume: 6 | Issue: 10 | Pages: 1097-1112

10.2217/imt.14.72 | PMID 25428648 Get It

Direct Cross-Priming by Th Lymphocytes Generates Memory Cytotoxic T Cell Responses
Kennedy, Richard B. , Undale, Anita H., Kieper, William C., Block, Matthew S. , Pease, Larry R. , Celis, Esteban , Kennedy, Richard

Mayo Clinic

The Journal of Immunology | April 23, 2014 | Volume: 174 | Issue: 7 | Pages: 3967-3977

10.4049/jimmunol.174.7.3967 | PMID 15778353 Get It

Abstract Under optimal Ag stimulation, CTL become functional effector and memory T cells. Professional APCs (pAPC) are considered essential for the activation of CTL, due to their unique capacity to provide costimulation and present exogenous Ags through MHC class I molecules. In this study, we report a novel means by which Th lymphocytes acquire and present MHC class I determinants to naive CTL. Although previous studies have looked at T cell Ag presentation to activated T cells, this study presents the first example of Ag presentation by Th cells to naive CTL. We report that activated Th cells can function as effective pAPC for CTL. Our results show that: 1) In addition to acquisition of cell surface molecules, including MHC class I/peptide complexes, from pAPC, Th cells can acquire and present MHC class I-binding peptides through TCR-MHC class II interactions with pAPC; 2) the acquired Ag can be functionally presented to CTL; and 3) Ag presentation by Th cells induces naive CTL to proliferate and preferentially differentiate into cells that phenotypically and functionally resemble central memory T cells. These findings suggest a novel role of Th cells as pAPC for the development of memory immune responses.
T Helper Lymphocytes Rescue CTL from Activation-Induced Cell Death
Kennedy, Richard B. , Celis, Esteban , Kennedy, Richard

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 177 | Issue: 5 | Pages: 2862-2872

10.4049/jimmunol.177.5.2862 | PMID 16920921 Get It

Abstract T cell activation is characterized by a vast expansion of Ag-specific T cells followed by an equally extensive reduction in T cell numbers. This decline is due, in part, to activation-induced apoptosis of the responding T cells during repeated encounter with Ag. In the current study, we used solid-phase MHC class I/peptide monomers to cause activation-induced cell death (AICD) of previously activated CD8 T cells in an Ag-specific manner. AICD occurred rapidly and was mediated primarily by Fas–FasL interactions. Most interestingly, we observed that Th cells could provide survival signals to CTL significantly reducing the level of AICD. Both Th1 and Th2 subsets were capable of protecting CTL from AICD, and a major role for soluble factors in this protection was ruled out, as cell-to-cell contact was an essential component of this Th-mediated protection. Upon encounter with Ag-expressing tumor cells, CTL underwent significant apoptosis. However, in the presence of Th cells, the CTL not only were protected against death, but also had significantly greater lytic ability. In vivo tumor protection studies using peptide immunization showed that the activation of Ag-specific Th cells was crucial for optimal protection, but did not affect the magnitude of the CTL response in the lymphoid tissues. In this study, we examine the type of help that CD4 T cells may provide and propose a model of Th cell–CTL interaction that reduces CTL death. Our results show a novel role for Th cells in the maintenance of CTL responses.